Global Long-acting Injectable Medications Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-03-14
- Report ID: 65878
- Pages: 117
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Long-acting Injectable Medications market in this environment.
In terms of revenue, this research report indicated that the global Long-acting Injectable Medications market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Long-acting Injectable Medications industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Eli Lilly aims at producing XX K Units Long-acting Injectable Medications in 2020, with XX % production to take place in global market, Nanomi accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Long-acting Injectable Medications Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Long-acting Injectable Medications Market
Eli Lilly
Nanomi
Alkermes
Zogenix
DURECT
Johnson & Johnson
MedinCell
Mapi Pharma
Oakwood Labs
GSK
Pharmathen
Kashiv BioSciences
...
Major Type of Long-acting Injectable Medications Covered in Prudent Markets report:
First-generation
Second-generation
Application Segments Covered in Prudent Markets Market
Schizophrenia
Contraception
HIV
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Long-acting Injectable Medications Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 First-generation -Product Introduction and Major Manufacturers
1.1.2 Second-generation -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Long-acting Injectable Medications Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Long-acting Injectable Medications Market
3.1.1 Top Companies leading Long-acting Injectable Medications Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Long-acting Injectable Medications Market
3.2.1 Top Companies leading Long-acting Injectable Medications Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Long-acting Injectable Medications Market
3.3.1 Top Companies leading Long-acting Injectable Medications Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Long-acting Injectable Medications Market
3.4.1 Top Companies leading Long-acting Injectable Medications Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Long-acting Injectable Medications Market
3.5.1 Top Companies leading Long-acting Injectable Medications Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Long-acting Injectable Medications Market
3.6.1 Top Companies leading Long-acting Injectable Medications Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Long-acting Injectable Medications Market
3.7.1 Top Companies leading Long-acting Injectable Medications Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Long-acting Injectable Medications Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Long-acting Injectable Medications Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Long-acting Injectable Medications Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Long-acting Injectable Medications Sales and Growth Rate (2021-2027)
5.2 Global Long-acting Injectable Medications Sales Value and Growth Rate (2021-2027)
6 Long-acting Injectable Medications Competitive Analysis
6.1 Eli Lilly
6.1.1 Eli Lilly Company Profiles
6.1.2 Eli Lilly Product Introduction
6.1.3 Eli Lilly Long-acting Injectable Medications Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Nanomi
6.2.1 Nanomi Company Profiles
6.2.2 Nanomi Product Introduction
6.2.3 Nanomi Long-acting Injectable Medications Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Alkermes
6.3.1 Alkermes Company Profiles
6.3.2 Alkermes Product Introduction
6.3.3 Alkermes Long-acting Injectable Medications Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Zogenix
6.4.1 Zogenix Company Profiles
6.4.2 Zogenix Product Introduction
6.4.3 Zogenix Long-acting Injectable Medications Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 DURECT
6.5.1 DURECT Company Profiles
6.5.2 DURECT Product Introduction
6.5.3 DURECT Long-acting Injectable Medications Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Company Profiles
6.6.2 Johnson & Johnson Product Introduction
6.6.3 Johnson & Johnson Long-acting Injectable Medications Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 MedinCell
6.7.1 MedinCell Company Profiles
6.7.2 MedinCell Product Introduction
6.7.3 MedinCell Long-acting Injectable Medications Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Mapi Pharma
6.8.1 Mapi Pharma Company Profiles
6.8.2 Mapi Pharma Product Introduction
6.8.3 Mapi Pharma Long-acting Injectable Medications Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Oakwood Labs
6.9.1 Oakwood Labs Company Profiles
6.9.2 Oakwood Labs Product Introduction
6.9.3 Oakwood Labs Long-acting Injectable Medications Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 GSK
6.10.1 GSK Company Profiles
6.10.2 GSK Product Introduction
6.10.3 GSK Long-acting Injectable Medications Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Pharmathen
6.12 Kashiv BioSciences
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
